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A B S T R A C T
Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of
inﬂammation, as well as many normal physiological functions in homeostasis and health, and anti-
microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF
biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector
functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF – now a
commonplace practice in the treatment of a wide range of human inﬂammatory diseases. With over ten
years of experience, and an emerging range of anti-TNF biologics now available, we also review their
modes of action, which appear to be far more complex than had originally been anticipated. Finally, we
highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally
delivered small molecule TNF-inhibitors, (ii) to speciﬁcally target selected TNF producing cells or
individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the
future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine
with society’s challenging expectations of durable treatment success and of achieving long-term disease
remission.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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This review summarizes the current state of knowledge on TNF/
TNFR molecules and discusses the reagents currently being used to
block TNF in the treatment of human diseases. It surveys the
beneﬁts and disadvantages of blocking TNF’s broad range of
biological activities in vivo and the reasons behind their
therapeutic efﬁcacy and limitations. This review will also debate
the most recent developments in the use of TNF and anti-TNF
agents: the search for ways to pre-identify treatment responders,
and the status of the search for the ‘‘holy grail’’ of selectiveAbbreviations: ADA, adalimumab; CNS, central nervous system; CER, certolizumab;
ETA, etanercept, etanercept; GOL, golimumab; Ig, immunoglobulin; IFX, inﬂiximab,
inﬂiximab; LTa, lymphotoxin-a; mAb, monoclonal antibody; NF-kB, nuclear
factor-kB; RA, rheumatoid arthritis; TNF, tumor necrosis factor TNF; TNFR, TNF-
receptor.
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3.0/).blockade of speciﬁc TNFR signaling pathways, not just in vivo but in
selected cells or speciﬁc organs, for optimal disease treatment
without the current known side-effects. Recent publications and
an emerging worldwide culture of embracing personalized
medicine suggest that this is not merely a laudable goal but will
soon become standard practice. Here we review the discovery and
development of anti-TNF agents in the treatment of human
diseases: from mediators of cell death and inﬂammation to
therapeutic giants – past, present and future, and oh what an
exciting future!
2. The discovery of TNF and the initial use of cytokines in
immunotherapy
TNF was discovered in 1975 as an endotoxin-inducible
molecule that caused necrosis of tumors in vitro [1]. Soon after
it was puriﬁed biochemically [2–4] and shown to be exquisitely
cytotoxic for L929 cells [5,6] and synergistic with interferons
[7,8]. TNF was quickly shown to be expressed by monocytes/
macrophages and activated T cells, distinct from another cytotoxice under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. TNF and TNFRs. Complex interplay between soluble and membrane bound
TNF and LTa ligands, and their cognate receptors. Membrane TNF is cleaved by
TACE to produce soluble trimeric TNF that binds TNFR1 and TNFR2. Membrane TNF
also binds both TNFR1 and TNF2 molecules. Another TNF-ligand cytokine LTa is
secreted as a homotrimer and/or found as a biologically active complex in
association with membrane bound LT-b. LTa binds TNFR1 as well as the herpes
virus entry mediator HVEM but not the LT-b receptor.
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were puriﬁed and characterized, the murine and human cDNAs
were cloned [12–14], and thus began the exciting era of anti-TNF
cytokine therapy.
Arguably the greatest interest in TNF came with the demon-
stration that TNF controlled tumor growth not only in vitro [5,6]
but also in vivo [15]. Early reports demonstrated that monocyte-
expressed TNF was capable of selective tumor cytotoxicity
[16]. However, the rapidly improving molecular biology capabili-
ties of that time quickly provided recombinant TNF, and the easy
preparation and availability of lipopolysaccharide (LPS), otherwise
known as endotoxin, meant that experimentally induced murine
tumors could be treated in vivo either by TNF directly, and/or by
LPS (endotoxin) – a biological inducer of TNF [1]. These studies
convincingly demonstrated TNF’s potent tumoricidal activity.
However, with this early success, it was initially overlooked that
the histopathological analysis had also revealed that the tumor-
icidal effects were both due to tumor necrosis and to tumor-
associated capillary injury [15,17]. Spurred on by the hope of it
being a non tumor-type speciﬁc anti-cancer therapeutic reagent,
together with its apparent safety in rodent models of disease,
recombinant TNF was quickly channeled into human clinical trials.
Phase I clinical trials began with recombinant human TNF
monotherapy. In all cases, diverse dose-dependent acute toxicities
were immediately evident, including fevers, chills, nausea (plus or
minus vomiting), shortness of breath, tachycardia and hypotension
[18–21]. Notably, these trials also reported that many patients
surprisingly experienced noticeable confusion soon after infusion.
Although a few patients experienced a transient beneﬁt there were
no long-lasting treatment responses and most patients eventually
succumbed to their tumors – due in part to the trials’ recruitment
of patients with high tumor burden [18–21]. TNF was also
administered after recombinant interleukin (IL)-2, but there was
still no signiﬁcant anti-tumor efﬁcacy recorded [22]. Overall, some
18 monotherapy Phase I trials and 10 Phase II trials, and another
18 combination trials were performed – without any signiﬁcant
success (for a detailed review see [23]). Taken together, and now
with the virtue of hindsight, the results of these trials revealed
that the broad biological ‘‘side effects’’ (diverse physiological
responses of TNF) far outweighed the preliminary indications of
TNF’s tumor cytotoxicity. Thus, the hopes of TNF being the great
‘‘tumor necrosis’’ factor and a cure for cancer were dashed, despite
extensive trials and much analyses.
Simultaneously with these events there was also signiﬁcant
attention being paid to the observation that neutralizing anti-
bodies to TNF (induced by passive immunization) protected mice
against lethal TNF-mediated endotoxemia [24]. These studies were
instrumental in proving that TNF is both potently tumorocidal, as
well as being an essential mediator of inﬂammation. In fact, what
quickly became evident was that TNF was a highly pro-
inﬂammatory agent, both independently, and via its ability to
induce expression of IL-6 [25,26]. These early ﬁndings represent
the seminal studies that directly lead to the opposite approach of
neutralizing TNF to inhibit inﬂammation. These were also the
initial revelations of an incredibly diverse range of physiological
functions of TNF. Today TNF is still widely regarded as arguably the
most pleiotropic of all cytokines described in mammals, with
activities spanning virtually every biological system from immune
system physiology to neurobiology and beyond.
3. TNF and TNF-receptor (TNFR) molecules: complex
interactions
TNF is a transmembrane 26 KDa protein expressed by activated
monocytes/macrophages (including central nervous system (CNS)
microglia), activated NK and T cells, but also by a diverse array ofnon-immune cells such as endothelial cells and ﬁbroblasts
[27,28]. The production of TNF mRNA is transcriptionally regulat-
ed, induced by nuclear factor-kB (NF-kB), c-Jun, activator protein-
1 (AP1) and nuclear factor associated with activated T cells (NFAT),
consistent with the presence of these transcription factor binding
sites within the promoter region of the TNF gene [29]. Post-
transcriptional mRNA regulation also occurs. This is largely by the
actions of miRNAs and RNA binding proteins, such as speciﬁc 30-
untranslated region AU-rich elements, tristetraprolin and mRNA
decay factors (for reviews, see [30,31]).
As a transmembrane protein expressed on the surface of cells,
membrane TNF (also sometimes referred to as pro-TNF) is cleaved by
a metalloprotease, TNFa-converting enzyme (TACE) [32,33]. This
liberates a trimeric soluble cytokine – the 17 KDa soluble TNF (sTNF).
This is the form of TNF found in blood plasma, i.e., the form that
circulates throughout the body and confers TNF with its potent
endocrine function – its ability to act at distant physiological sites,
far away from the site of its synthesis. Both soluble and membrane
TNF bind to two transmembrane receptor molecules: TNFR1 (also
sometimes referred to a p55/p60) – a death-domain-containing
protein, and TNFR2 (also known as p75/p80) [34] (see Fig. 1).
Interestingly membrane TNF is a more potent ligand for TNFR2 [35],
and while most cells express constitutive but low levels of TNFR1,
only some cells express detectable surface TNFR2 [36]. However, the
expression levels of TNFR proteins can be regulated by cytokines,
especially by interferons [37,38], which explains, in part, the noted
synergy between TNF and interferons [7,8].
Whilst the molecules comprising the TNF/TNFR system are all
well deﬁned biochemically, the biological interactions of ligand
and its receptors are not so simple. For example, complex models
for soluble TNF (ligand) passing between receptors have been
proposed [39], and TNFR-binding to membrane TNF is capable of
resulting in ‘‘reverse signaling’’, that is, signaling back into the
membrane TNF producing cells [40]. In this context the intracellu-
lar regions of membrane TNF can become phosphorylated [41] and
signal transduction can result in the activation of NF-kB, i.e., within
the TNF-producing cell [42,43]. Thus, reverse signaling can lead to
altered cytokine expression by the same TNF-producing cell
[44–46]. On the other hand, membrane TNF reverse signaling by
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monocytes to LPS, resulting in reduced production of IL-1, IL-6 and
IL-10 [47]. In addition, overexpression of the receptors alone, either
in vitro or in vivo, can spontaneously induce TNFR signaling
independent of ligand [48]. This feature is used extensively in in
vitro assays demonstrating functional TNFR signaling and is largely
due to overexpression-mediated TNFR oligomerization. Further-
more, lymphotoxin (LT)-a (LTa) is another TNFR1 ligand. It too has
high afﬁnity for TNFRs but it usually acts quite independently of
TNF (see Fig. 1). The complexity of TNF ligand/receptor interactions
cannot be understated since LTa binds both to TNFR1 and another
TNF-R family protein, the herpes virus entry mediator (HVEM).
Moreover, LTa in complex with LTb, binds to the LTb receptor (for
review on TNF, LTa and their receptors see [49]) (see Fig. 1).
4. TNF-induced TNFR signaling: diverse pathways of apoptosis
and inﬂammation
A plethora of in vitro studies have revealed complex and
divergent TNF-R signaling pathways. Generally speaking there are
distinct TNFR-speciﬁc signaling pathways, which are extraordi-
narily complex, but which account for all aspects of TNF’s ability to
induce both cell death and/or co-stimulation and cell activation.
Generally speaking the process begins via the association of TNFR1
or TNFR2 proteins forming trimers and this is required for TNF-
binding. The trimers themselves are probably only transiently
expressed on the cell surface, as they are notoriously difﬁcult to
visualize in that location (Gale A and Sedger LM, personal
observations). Signaling-competent TNFR trimers undergo a
conformational adjustment that requires the pre-ligand assembly
domain (PLAD) which is located within the N-terminal cysteine-
rich domain (CRD) of many TNFR-family molecules [50]. This
PLAD-dependent TNFR trimer adjustment is thought to be required
to permit TNF binding and ligand-induced receptor signaling
[50]. On other hand, it is unclear if a PLAD-mediated conforma-
tional change is required for ligand-independent (overexpression
induced) receptor signaling.
4.1. TNFR-induced cell death
TNF-induced cell death signaling is carried out by TNFR1
[51]. This requires the release of an intracellular TNFR inhibitor, the
silencer of death domain (SODD) protein [52,53]. Essentially,
PLAD-stabilized TNFR interactions permit the release of SODD and
the recruitment of intracellular ‘‘death signaling inducing signaling
complex’’ (DISC) proteins, including TNFR-associated death
domain protein (TRADD), Fas associated protein with death
domain (FADD) and the TNFR-associated factor (TRAF)-1 [54–
57]. These proteins create a scaffold permitting the recruitment of
additional proteins such as the initiator caspase, pro-caspase-8,
which, when proteolytically cleaved, releases an active form of
caspase-8 [58]. The freed, active, caspase-8 then enzymatically
processes pro-caspse-3, -6, -7, and other cytosolic substrates,
converting these executioner pro-caspases themselves into active
enzymes [59]. The activation of caspase-3, in particular, is essential
for TNF-induced cell death, as it targets a latent DNAse that
degrades genomic DNA [60] thus causing apoptotic cell death; the
caspase activated DNase (CAD) [60]. The protease activity of
caspase-8 is tightly regulated by a negative inhibitor protein FLICE/
caspase-8 inhibitory protein (cFLIP). cFLIP lacks a death-domain
but contains a death-effector domain (DED) that permits its
interactions with pro-caspase-8 as well as other DED containing
proteins [61], thus preventing constitutive pro-caspase-8 recruit-
ment to the TNFR1 DISC. The inhibitor of apoptosis proteins (IAPs)
are also important regulators of TNFR-induced cell death. IAPs act
by virtue of their direct interaction with TRAF2 [62,63]. Thus, TNFinteraction with TNFR1 induces a caspase-dependent apoptotic
cell death that is critically regulated by cFLIP and IAPs. Although
TNF-induced cell death is well characterized, it does not often
occur without provocation or cellular pertubation, that is, not
unless there is some sort of aberration or inhibition of the cell cycle
[64], protein synthesis, or altered cell metabolism [65]. As such,
TNF is a powerful inducer of apoptotic cell death, but, as originally
stated, usually only in transformed cells (cancer cells) [66,67],
virus infected cells [68,69], biochemically imbalanced or stressed
cells, not in most normal primary mammalian cells.
4.2. TNFR-induced NF-kB
In contrast to its name, TNFR signaling generally does not kill
most cells, but instead, it results in the activation of NF-kB and/or
several additional non-death signaling pathways. TNFR signals NF-
kB activation for cell survival by recruiting TRADD and TRAF2,
which results not only in the activation of NF-kB but also in
signaling via mitogen activated protein kinase (MAPK) and c-Jun-
terminal kinase (JNK) [70]. Here, TRAF2 interacts with MAPK
kinases, that permits the activation of JNK, p38 SAP kinase and
MAPK [71,72]. TRAF2 is therefore critical to TNFR-induced
activation of NF-kB because TRAF2 and receptor interacting
protein kinase (RIP) activate the inhibitor of NF-kB kinase (IKK),
as well activating the IKK-activating kinase, NF-kB-inducing
kinase (NIK) [73]. Upon the phosphorylation and ubiquitin-
dependent degradation of IKK, NF-kB transcription factors
translocate into the nucleus where they bind to DNA and function
as transcriptional activators. Moreover, NF-kB itself can transcrip-
tionally induce TNF, as well as TRAF1 and TRAF2 genes, and thereby
further amplify TNF/TNFR signaling pathways [74]. Furthermore,
the activation of JNK and its subsequent signaling activates
transcription factors c-Jun, AP1 and ATF2 [75,76]. Hence, these
pathways explain the ability of TNF to induce other inﬂammatory
cytokines such as IL-6 and IL-8, and TNF’s ability to induce [77] and
synergize with interferons [8,78].
This classical NF-kB activation pathway reverts to a non-
canonical, or alternate NF-kB signaling pathway in situations
where TRAF2/3 or IAP are blocked [79]. Under these circumstances
NIK abundance is stabilized, which allows NIK-dependent
processing of NF-kB2 p100 [80–82]. [Note: the classical pathway
proceeds ﬁrst because the cIAP/TRAF2/3 complex constitutively
degrades NIK in normal circumstances]. TNF and TRAF3 are
important in activated T cells [83], where expression of an
alternatively spliced form of TRAF3 (lacking exon 8) allows for non-
canonical activation of NF-kB [84] and, while the mechanism(s)
that control the differential regulation of TRAF3 alternate splicing
are not known, it has recently been shown that T cell-speciﬁc
TRAF3/ mice produce twice the normal number of TNFR2-
expressing T regulatory cells (Tregs) [85]. Nevertheless, taken
together, TNF-induced NF-kB is important in inﬂammation since
NF-kB is a global trans-activator of numerous pro-inﬂammatory
cytokines, chemokines, and their receptors, and a critical regulator
of leukocyte activation and function.
4.3. TNFR-induced ubiquitination and viral deviation
The full spectrum of TNF-signaling molecules involved in these
pathways is actually quite broad and these pathways are described
above in relatively simpliﬁed terms. In fact there are a number of
additional, more recently described, proteins involved in TNFR
signaling, such as HOIL-1, HOIP and Sharpin. These molecules are
recruited to the TNFR-signaling complexes, where they function in
the linear ubiquitination and degradation of RIPs and NEMO/IKKg
[86–90]. There are also a number of variations to these TNFR cell
death and NF-kB pro-proliferation pathways. For example,
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in the apoptosis process [91–93]. Moreover, JNK activation is not
always pro-proliferative, but can drive apoptosis through the
cleavage of the BH3-only protein BID (at a different site to that
which is cleaved by capase-8) leading to release of second
mitochondrial-derived activator of caspase Smac/DIABLO and
mitochondrial-mediated apoptosis [94,95].
Given the potent anti-viral activity of TNF [68,69], which is
mediated through both TNFRs [96], one must also consider
signaling in the context of virus infection. In this regard it is
worth noting that many viruses have evolved to encode and
express molecules that speciﬁcally inhibit almost every step of
TNFR-induced apoptosis [97] and NF-kB signaling pathways
[98,99]. Indeed most poxviruses viruses express a pan-caspase
inhibitor such as CrmA [100,101], and certain herpes viruses
encode a viral-FLICE that inhibits caspase-8 [102]. In cells infected
with these viruses ‘‘normal’’ TNF/TNFR1 signaling is blocked
[68,69] and TNFRs induce cell signaling via a RIP kinase-dependent
cell death pathway that results in a form of TNF-induced cell death
described as ‘‘programmed necrosis’’ [103].
4.4. TNFR-induced inﬂammation
A review of TNFR signaling must also consider that TNF ligation
of TNFRs also leads to non-apoptotic and non-proliferative
signaling pathways. These include acid and neutral sphingomye-
linase pathways and the activation of 5-lipoxygengase and
phospholipase A2 enzymes, that result in the production of
arachindonic acid, 5-hydroxyeicosatetraenoic acid (5-HETE) and
proinﬂammatory leukotrienes [104]. The sphingomylinase path-
way leads to the production of diacyl glycerol and subsequently to
the activation of protein kinase C, and eventually NF-kB
(independent of TRAF-activated NF-kB [105,106]). This results in
the expression of pro-inﬂammatory cytokines and chemokines but
also in production of prostaglandins [107]. There is also the
recruitment of a molecule known as Fas-associated with neutral
sphingomyelinase (FAN), to a membrane proximal domain in
TNFRs [108], and the actions of acid sphingomylinase that result in
production of ceramides. Ceramides induce active cathepsin D, an
aspartate non-caspase protease that can target BID [109,110]. Thus
FAN connects the TNFR biology to the plasma membrane, and more
speciﬁcally, to cytoskeletal re-organisation, ﬁlopodium formation,
and macropinocytosis [111], and hence to processes of leukocyte
migration [112]. Ceramide is also a powerful inﬂammatory
intermediate involved in several cellular processes including cell
migration, proliferation, and apoptosis (for review see [113]). Thus,
the effects of TNF-induced TNFR signaling pathways are diverse,
and varied in different cell types, and speciﬁc circumstances –
explaining TNF’s pleiotropic properties.
5. TNF in vivo biology – animal models and human diseases,
what do they tell us?
5.1. TNF – a physiological mediator of inﬂammation
TNFs’ stimulation of globally activating transcription factors
such as NF-kB, and its signaling via bio-active lipids that induce
arachidonic acid, 5-HETE and ultimately leukotrienes and pros-
taglandins, explain its effects on diverse cells within almost every
human physiological system. They also explain TNFs powerful pro-
inﬂammatory capacity, especially within immune cells capable of
producing a cascade of downstream cytokines and chemokines. For
example TNF promotes monocyte/macrophage differentiation
[114,115], can enhance activated B cell proliferation [44]
concomitant with an autocrine increase in TNFR expression
[116,117]. It promotes the proliferation of ﬁbroblasts [118,119]and is a powerful inducer of inﬂammation, often acting together
with together with IL-1b [120]. Depending on the cell type it is
produced by, or acts upon, TNF (with or without IL-1b) is a potent
inducer of IL-6 [25,26] and the further production of TNF itself
[121]. In fact circulating IL-6 is signiﬁcantly elevated in healthy
humans infused with recombinant human TNF, and/or TNF and
IFNg, even when administered locally [122,123], or during bacterial
infection [124,125]. Together these cytokines are the central
mediators of endotoxic shock which is physiologically regulated
via the natural production of soluble IL-1 receptor antagonist
(IL-1Ra) and/or soluble TNF-receptors (for review see [126]).
5.2. TNFR biology in genetically predetermined autoinﬂammation
The role of TNF inﬂammation was further conﬁrmed by the
observation that germline mutations in TNFR extracellular
domains deﬁnes a family of dominantly inherited auto-inﬂamma-
tory syndromes, known as ‘‘TNF-receptor associated periodic
syndrome’’ or TRAPS [127]. Presenting with a range of symptoms,
but predominately as unexplained episodes of fever and inﬂam-
mation, TRAPS patients represent nature’s version of a structure/
function mutational experiment. A number of theories as to why
germline TNFR extracellular domain mutations result in fever and
autoinﬂammation have been proposed, including aberrant folding
[128,129], spontaneous overexpression, aggregation and constitu-
tive TNFR signaling [130]. However, abnormal ER retention [131],
mitochrondrial reactive oxygen species [132], ER stress, and the
stress response to ‘‘unfolded’’ or aggregated proteins also
contribute to TRAPS pathogenesis [133]; for review see [134]. In
most cases of TRAPS, fever and inﬂammation are reﬂected in
elevated inﬂammatory mediators, of which TNF, IL-6 and IL-1b are
central [135]. Consistent with this, most TRAPS patients respond
well to treatment with TNF or IL-6 inhibitors [136,137], although
not without complications or incomplete remission, and these
treatments often fail to reduce the elevated levels of acute phase
proteins (for reviews see [135,138]). Nevertheless, the ﬁndings
that humans with naturally occurring TNFR mutations present
with transient spontaneous fevers and inﬂammation represent the
ultimate biological evidence that TNF and TNFRs are central
components of inﬂammation.
5.3. TNF has direct anti-viral and anti-bacterial activity
TNF is one of the most potent anti-viral cytokines described to
date. It acts alone or in synergy with interferons [68,139] and its
anti-viral activity requires both TNFR1 and TNFR2 [96]. Here, TNF
plays several hands simultaneously: it is required for inﬂammatory
cell recruitment, acting largely through TNF-induced chemokine
expression, and its ability to induce inﬂammatory mediators that
act as potent chemoattractants for innate immune cells such as
neutrophils, monocytes, natural killer cells and antigen presenting
cells, including immature or tissue resident macrophages and
dendritic cells [140–142]. TNF, through its potent activation of NF-
kB, appears to be integral to the maturation of these myeloid cells
into their functionally mature effector phenotypes [140–142]. For
example, immature tissue resident dendritic cells require NF-kB to
convert them into mature antigen presenting cells, that stimulate
naı¨ve T cells in nearby draining lymph nodes and initiate antigen-
speciﬁc T and B cells responses. It also inﬂuences macrophage
differentiation, promoting M1 phenotype cells, over the alternati-
vely activated and largely tolerogenic M2 cell-subtype [143,144].
As a membrane bound molecule TNF provides B cell ‘‘help’’,
thereby promoting antibody production [145]. TNF is also directly
anti-viral via its direct induction of TNFR1-mediated apoptotic cell
death [69]. In this scenario TNF is directly cytotoxic, speciﬁcally
killing the virus-infected cells prior to maximal virus replication,
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potency of TNF-anti-viral activity is reﬂected in the fact that many
human pathogenic viruses have evolved sophisticated strategies to
speciﬁcally subvert various molecules in the TNF/TNFR axis [97]. Of
these, the poxviruses are particularly noteworthy, evolving to
encode viral TNFR-homologous genes that produces soluble TNFR
‘‘decoy’’ receptors [146]. In many ways these viral TNFR molecules
can be considered the prototype of Etanercept (Enbrel1), binding to
soluble TNF with high afﬁnity [147–149] and inhibiting TNF’s
cytotoxicity and inﬂammatory properties [150].
5.4. TNF in neurobiology
TNF has incredibly broad biological effects that are far beyond
the scope of this manuscript. Sufﬁce that we brieﬂy pay attention
to this most under-appreciated area of TNF biology: the role of TNF
in neurobiology. This is an exciting area of research that is only
recently enjoying the spotlight, as neuroscience research rapidly
expands and joins hands with immunology. Intriguingly, the TNF/
IL-1b/IL-6 axis in LPS-challenge has been shown to also involve a
neurological response, physiologically linking systemic inﬂamma-
tion with subsequent neurological and neuropsychiatric condi-
tions [151]. Even peripheral inﬂammation, by LPS, Toll-like
receptor (TLR) stimulation or TNF, induces increased local brain
TNF expression in mice [152]. These ﬁndings represent the tip of
the iceberg as there is now considerably attention being paid to the
physiological role of TNF in the central nervous system (CNS),
especially in psychological and neurological conditions. What is
clear is that cytokines such as TNF, IL-1 and IFNg are produced by
glial cells in the CNS, but whether TNF plays a protective or
pathological role appears to depend highly on the context (for
reviews see [153,154]). Excess TNF is also implicated in neuronal
toxicity acting syneristically with glutamate, albeit in neuronal
cells in vitro [155]. Of particular note, however, is the recent
demonstration that sympathetic neurons express membrane TNF
that are capable of reverse signaling, which is important for
neuronal growth and branching during post-natal development
[156]. This study may be the ﬁrst to provide a convincing exampleFig. 2. Current anti-TNF biologics (including biosimilars) and their biological properti
inﬂiximab (IFX), and humanized or fully human Fv (green) anti-TNF monoclonal Ig adalim
Ig Fc etanercept (ETA), pegylated recombinant extracellular TNFR1 onercept (ONE) andof a physiologically important role for soluble TNFR and TNFR
reverse signaling independent of infection, inﬂammation or
immunopathology [156]. There is also now an increasingly large
bank of publications emerging that strongly implicate a role for
TNF in conditions with cognitive impairment, bipolar disorder
(especially during episodes of mania and/or depression), and in
CNS tissue injury. Further detailed knowledge of the physiological
role of TNF in normal CNS tissue is therefore urgently needed,
especially given that the capacity to co-treat these conditions with
TNF neutralization is being actively explored (discussed below).
6. Anti-TNF therapeutics – What are they?
Despite the broad dose-limiting toxicities preventing the use of
TNF as a chemotherapy agent, the potential to block TNF in
inﬂammatory disease has remained evident from the very early
days. Moreover, the long functional half-life and in vivo safety of Ig
immediately suggested that anti-TNF antibodies would ameliorate
TNF-mediated inﬂammation. Several TNF-speciﬁc monoclonal
antibodies (mAbs) and recombinant fusion proteins have been
produced. Their development and human therapeutic uses are
summarized below.
6.1. Inﬂiximab (abbreviated here as IFX), trade name Remicade1
A human TNF-speciﬁc neutralizing antibody, inﬂiximab (ab-
breviated here as IFX), trade name Remicade1, was developed in
the late 1990’s. This anti-TNF chimeric mAb reagent comprises the
murine immunogloblulin (Ig) heavy (H) and k light (L) chain
variable (V) regions with speciﬁcity for human TNF, and human
IgG1 Ig constant (C) regions [157] (see Fig. 2). IFX binds to soluble
and membrane TNF, and when bound it prevents TNF from binding
to its receptors; it therefore prevents ligand triggered TNF-R
signaling [157,158]. IFX was highly successful therapeutically,
even from the ﬁrst of many clinical trials [159]; it is an effective
inhibitor of TNF-induced inﬂammation in a range of human
diseases, including the spectrum of rheumatic inﬂammatory
diseases as well as Crohn’s disease (see Table 1).es. Shown are chimeric mouse Fv (red) human Fc (gray) anti-TNF monoclonal Ig
umab (ADA), golimumab (GOL) and humicade (HUM). TNFR-based TNFR2: human
 pegylated human IgG1 Fab’ certolizumab pegol (CET).
Table 1
List of currently available anti-TNF therapeutics and their approved indications.
CURRENT ANTI-TNF BIOLOGICS
Drug name & structure Brand name
(Company and ﬁrst aproval date)
Route/Half-life/co-therapya Approved disease indications Website
Etanercept
Recombinant fusion protein:
Human TNFR2:IgG1-Fc
Enbrel1
(Immunex/now Amgen (US), and
Pﬁzer (UK))
FDA registered Nov.1998
s.c.
injection,
2–4 weeks
25 mg vial
50 mg/mL
 Rheumatoid arthritis
 Polyarticular juvenile idiopathic
arthritis
 Psoriatic arthritis
 Ankylosing spondylitis
 Plaque psoriasis
enbrel.com
Inﬂiximab
Humanized (chimeric)
IgG1k mAb
Remicade1
(Centocor Ortho
Biotech Inc. (US) and
Janssen-Cilag Pty Ltd. (UK)).
FDA registered Aug. 1998
i.v. infusion
4 weeks
100 mg vial
 Rheumatoid arthritis*
 Psoriatic arthritis*
 Ankylosing spondylitis
 Plaque psoriasis
 Crohn’s disease (moderate/severe)
 Pediatric RA & Pediatric Crohn’s
remicade.com
Adalimumab
Human IgG1k mAb
Humira1
(ABBVRIE Inc.)
FDA registered Dec. 2002.
s.c. injection
2–4 weeks,
40 mg/0.8 mL syringe/vial
 Rheumatoid arthritis*
 Psoriatic arthritis*
 Plaque psoriasis
 Active ankylosing spondylitis
 Crohn’s disease (moderate/severe)
 Juvenile idiopathic arthritis (severe)
humira.com
Golimumab
Human IgG1kmAb
Simponi1
(Centocor Ortho Biotech Inc.)
FDA registered Apr. 2009.
s.c. injection
2 weeks
50 mg injection
 Ulcerative colitis
 Rheumatoid arthritis*
 Psoriatic arthritis*
 Plaque psoriasis
 Ulcerative colitis
simponi.com
Certolizumab Pegol
Pegylated-Fab’ fragment of humanized
IgG1k mAb
Cimzia1
(UCB Pharma SA)
FDA registered Apr. 2008
s.c. injection
200 mg injection
 Rheumatoid arthritis*
 Psoriatic arthritis*
 Ankylosing spondylitis
 Crohn’s disease (moderate/severe)
cimzia.com
CTP-13 Humanized (chimeric)
Inﬂiximab biosimilar IgG1k mAb
Remsima1; Inﬂiximab
(Celltrion Healthcare Inc)
and Inﬂectra1 (Hospira)
tba  Rheumatoid arthritis*
 Psoriatic arthritis*
 Ankylosing spondylitis
 Plaque psoriasis
 Crohn’s disease (moderate/severe)
 Pediatric RA & Pediatric Crohn’s
tba
PREVIOUS PIPELINE ANTI-TNF BIOLOGICS
Drug name & structure Brand name (Company) Route Targeted/disease
indications
Major clinical
trials
CDP571
Humanized IgG
anti-human TNF mAb
Humicade
(discontinued)
N/a Crohn’s disease [213,214,
351,352]
Onercept
Pegylated dimeric
extracellular Human TNFR1
Serono
(discontinued)
N/a Crohn’s disease [353–358]
a Route of drug administration: sub-cutaneous injection (s.c.) and intravenous (i.v).
Approved as monotherapy and/or with methotrexate (MTX) for RA or psoriatic arthritis*, or for multiple myeloma combined with dexamethasone, as indicated.
Tba; to be announced.
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ADA is another anti-TNF neutralising IgG that was ﬁrst assessed
in clinical trials in 2002. In this case the IgG was a fully human IgG1
(see Fig. 2) – theoretically minimizing the potential to elicit anti-
mouse mAb Ig, speciﬁc to the murine Ig Fv component of IFX mAb.
Phase I trials demonstrated safety, favorable pharmacokinetics,
and efﬁcacy for rheumatoid arthritis (RA), when administered with
or without methotrexate [160–162].
6.3. CD571 (also known as Humicade1)
Soon afterwards CDP571 (Humicade1), a human IgG4 anti-TNF
mAb was also developed (see Fig. 2). It too, bound human TNF with
high afﬁnity, and blocked TNFs cytotoxic activity. Known as
Humicade1 it was able to neutralize TNF in in vivo animal models,
similarly to IFX and ADA, and yet it surprisingly failed todemonstrate efﬁcacy in a clinical trial for Crohn’s disease and
was not developed further [163–166]. (Potential reasons for the
failure of Humicade in the clinic may have subsequently become
evident and are discussed below).
6.4. Etanercept (abbreviated here as IETA), trade name Enbrel1
A novel TNF-Receptor: Ig fusion protein was developed and FDA
approved in 1998. ETA comprises the extracellular region of
human TNFR2 expressed as a fusion protein with a C-terminal
human IgG1 crystallizable fragment (Fc) domain [166] (see Fig. 2).
This reagent was the ﬁrst recombinant receptor:Ig fusion protein
approved for therapeutic use in humans; it bound to human TNF
with an afﬁnity comparable to endogenous TNFR2, and blocked
TNF’s cytotoxicity and inﬂammatory capacity [163–166]. It was
successful in clinical trials and is still broadly used in inﬂammatory
diseases (see Table 1).
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Ten years or more later, and patent protection for IFX, ADA and
ETA aside, additional anti-TNF agents have now emerged.
Golimumab (GOL), trade name Simponi1, is a fully humanized
IgG1 anti-TNF (see Fig. 2) with an Ig Fc identical to IFX but an
engineered human Fv Ig sequence [167]. It is effective in the
treatment of rheumatoid arthritis (RA), psoriatic arthritis and
ankylosing spondylitis, and even for RA patients who experienced
little beneﬁt or adverse events from IFX [167–169].
6.6. Certolizuman Pegol (abbreviated here as CERT): trade name
Cimzia1
Certolizumab (CERT) is a pegylated dimeric Ig Fab’-domain of a
TNF-speciﬁc IgG1 mAb (see Fig. 2). Of note, the PEG-component,
which reduces immunogenicity and improves in vivo half-life
[170], was speciﬁcally engineered for attachment to the C-
terminus of the Ig Fab’ in a manner that does not interfere with
the Fab’s TNF-speciﬁcity and TNF-neutralizing properties [171]. It
has demonstrated efﬁcacy, with or without co-immunosuppres-
sant agents, for patients with moderate-to-severe Crohn’s disease
[172,173]. For recent excellent reviews on the properties of these
newer anti-TNF agents see [174,175]; for a summary of the
approved uses of all currently available anti-TNF biologics see
Table 1.
6.7. Onercept (abbreviated here as ONE)
Several other biological anti-TNF reagents, such a onercept
(ONE), a soluble recombinant human TNFR1 were also developed
[176]. These reagents all demonstrated efﬁcacy in early, i.e., pre-
clinical, animal models of inﬂammatory disease [177,178]. Al-
though early data indicated these molecules were safe for in vivo
administration, they exhibited relatively slow absorption rates,
and short in vivo half-lives, and this appeared to correlate with
minimal clinical efﬁcacy in Phase II and III treatment trials of
moderate-to-severe plaque psoriasis, even with pegylated versions
for more favorable pharmacokinetics [179].
The anti-TNF agents IFX, ADA, ETA, GOL and CERT all comprise
either high afﬁnity human TNF-speciﬁc mAb or TNFR-extracellu-
lar IgFc engineered mAb domains, and as such, they all exhibit
high-speciﬁcity for human TNF. Since ETA and ONE are literally
TNFR proteins they also interact with LTa – similar to the native
TNFRs (see Fig. 1). Note: LTa binds TNFR1, in addition to HVEM,
but not TNFR2 [49], as shown in Fig. 1. Thus these reagents are all
functionally capable of blocking TNF from binding to TNFR1 and/
or TNFR2, either through steric-hindrance or because the anti-
body’s epitope overlaps with the TNF/TNFR ligand/receptor
interaction sites. They are, therefore, all high-afﬁnity agents
capable of neutralizing TNFs cytotoxicity in vitro and in
vivo. Moreover, due to their in vivo safety and anti-inﬂammatory
disease efﬁcacy, IFX, ADA, ETA, GOL, and CERT are now licensed
and approved for human therapeutic use worldwide; they are
approved by the US Food and Drug Administration (FDA), the
British Medicines and Healthcare Products Regulatory Agency
(MHRA), and numerous other therapeutic regulator bodies such as
the European Medicines Agency (EMA), the Australian Therapeu-
tic Goods Administration (TGA), South African and Latin American
and other health product regulatory bodies. They are approved for
clinical use in the inﬂammatory diseases: RA and psoriatic
arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s
disease and/or ulcerative colitis (see Table 1). Their consumer
uptake depends essentially on pricing, availability and clinician
preferences.6.8. Biosimilars
A number of biosimilars (aka similar biological medicinal
products), or ‘‘follow-on’’ anti-TNF drugs also now exist
[180,181]. These are, by deﬁnition, ‘‘copy-reagents’’ produced by
manufacturers who produce an analogous reagent by virtue of
having access to the original innovator drug but without access to
the original clone or manufacturing process (a trade secret
protected by patent law). They are therefore theoretically identical
in biological activity, yet they may differ in clinically inactive
components, usually due to differences in manufacturing process-
es [180,181]; (biosimilars are distinct from ‘‘generic’’ pharmaceu-
ticals – a term usually preferred for small-molecule inhibitor type
drugs of identical active ingredient and equivalent quality, and
usually sold without reference to the original brand-name).
Through a streamlined process they must be assessed in at least
one ‘‘non-inferior’’ clinical trial prior to FDA and EMA approval. The
ﬁrst of these is CTP-13 (Remsima1; Inﬂectra1). CTP-13 is an
identical copy anti-TNF innovator mAb IFX. Recent reports of
randomized double-blind, multi-center (multinational) trials
found that CTP-13 is as effective as IFX in the treatment of active
RA, when assessed by European League Against Rheumatism
(EULAR) response criteria [182] and by change in disease activity
scores, with similar pharmacokinetics in ankylosing spondylitis
patients [183].
6.9. Other agents: curcumin
One of the longest known natural anti-inﬂammatory agents is
curcumin. It is chemically deﬁned as (1E,6E)-1,7-bis(4-hydroxy-3-
methoxyphenyl) hepta-1,6-diene-3,5-dionediferuloymethanne),
but better known as diferuloylmethane, and an abundant
component of the spice turmeric. Curcumin is a naturally produced
compound that inhibits TNF and other pro-inﬂammatory cytokines
including TNF, IL-1b and IL-6; it is a broad-acting anti-TNF and
anti-inﬂammatory nutraceutical, generally consumed orally via
natural food spices and/or via medicinal preparations (for reviews
see [184,185]). Despite its long-known medicinal anti-inﬂamma-
tory activity, it is poorly soluble in aqueous solutions. However, it
is pharmacologically well characterized and considered safe even
at high concentrations [186,187]. Nearly 100 clinical trials for
curcumin are currently listed at http://www.clinicaltrials.gov and
due to its newly appreciated neuroprotective effects [188,189] it is
also being actively investigated in several neurological conditions,
including Alzheimer’s disease [190].
6.10. Other agents: thalidomide
Thalidomide (brand names Immunoprin1, Talidex1, Talizer1,
Thalomid1) is chemically deﬁned as RS)-2-(2,6-dioxopiperidin-3-
yl)-1H-isoindole-1,3(2H)-dione. It was initially developed in the
early 1960’s as a sedative and hypnotic agent [191], but it quickly
became known for its anti-nausea properties and was conse-
quently sold without prescription to thousands of pregnant
women to treat ‘‘morning sickness’’. Soon afterwards, however,
children were born with severe malformations, revealing its
teratogenic capacity [192]. Amongst a wide spectrum of biological
activities, thalidomide was also found to inhibit the production of
TNF, primarily by suppressing TNF-induced NF-kB [193] (for
review see [194]). It has therefore been reborn as an effective
agent in the treatment of erythema nodosum leprosum (ENL, a
complication of leprosy) and multiple myeloma [195]. Just like
curcumin, discussed above, it has recently been reported to
attenuate inﬂammation in CNS pathologies, such as Alzheimer’s
disease [196,197].
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All anti-TNF agents described above bind to soluble and
membrane TNF with high afﬁnity and speciﬁcity, and they all
prevent TNF from binding to TNFRs (see Fig. 3, panel A and B). By
blocking TNFR activation they prevent all of TNFs ability to induce
inﬂammation, including all downstream mediators such as TNF/
TNFR-induced IL-6 – a potent mediator of TNF-induced inﬂamma-
tion [25,26]. Other mechanisms that contribute to the biological
activity of these anti-TNF reagents include their ability to bind to
membrane TNF and hence to induce reverse signaling in
membrane TNF-expressing cells [198–201] (see Fig. 3, panel C).
For reagents that comprise Ig components, their ability to engage
with IgG Fc receptors (FcR) provides a mechanism for their
involvement in antibody-dependent cell-mediated cytotoxicity
(ADCC), especially via myeloid-lineage cells and the Fc moiety
permits complement-dependent cytotoxicity (Fig. 3, panel C).
These properties are not shared by all current anti-TNF agents, in
part because they do not all contain an FcR-binding region; this
feature likely contributes, in part, to their varied effectiveness in
disease modifying capabilities [202]. However, it’s apparent that
mechanisms of anti-TNF biologics are complex and not completely
understood, for while IFX ameliorates both RA and Crohns’s disease
severity, ETA shows minimal or no efﬁcacy in Crohn’s – despite its
effectiveness for RA and related rheumatic diseases [203,204]. One
explanation is that IFX, but not ETA, results in production of the
immunosuppressive cytokine IL-10 (which might occur through
reverse signaling from membrane TNF [205]). However, this is
unlikely to completely account for their differential effectiveness,
since TNFR2 is also a potent agonist for membrane TNF [35] and
ETA is a human TNFR2 fusion protein, and hence capable of
inducing TNF reverse signaling, even if less so than anti-TNF Igs
[206]. Alternative explanations are that IFX can induce T cell
activation-induced cell death [207,208], or that anti-TNF anti-
bodies inhibit T cell proliferation and cytokine secretion and
induce regulatory macrophages via FcR interactions [209]. Howev-
er, in a direct comparison study, IFX, ADA and ETA were all shown
to induce monocyte and lymphocyte apoptosis to similar extents
[171,210]. Perhaps more relevant to inﬂammatory bowel disease,
where the microbiome (the population of microorganisms that
inhabit gut, skin, mouth and elsewhere in the body) is strongly
implicated in disease etiology, this study also demonstrated that
IFX, ADA and CERT are able to inhibit LPS-induced monocyte IL-1b
while ETA is less effective at doing so [171,210]. Consistent withFig. 3. Mechanisms of action of anti-TNF biologics. Anti-TNF biologics bind and neutralize
Fc-R expressing cells, possibly with simultaneous engagement with TNF expressing cells
membrane bound forms of LTa cytokines (panel D).this argument, membrane TNF reverse-signaling has been shown
to downregulate LPS-induced TNF, IL-1 and IL-6 [47]. Thus, it is
possible that the difference in clinical effectiveness in anti-TNF
biologics in Crohn’s reﬂects their relative ability to induce
membrane TNF reverse signaling with concomitant engagement
with FcR-bearing cells (Fig. 3 panel C). Finally, it should not be
forgotten that ETA, and ONE, both comprising native TNFR
extracellular proteins, can also bind and neutralize LTa as well
as LTa1b2, and LTa2b1, with or without FcR interactions (see
Fig. 3, panel D).
Another major difference between the anti-TNF molecules is
that they are administered by different routes and have different in
vivo pharmokinetics and pharmacodynamics [211,212]. Also, some
molecules do not contain an IgG Fc-region (see Fig. 2) that prolongs
their life-span in plasma, and even those that do, will not all bind
FcR’s. For example, the Ig Fc-region component of CDP571 (HUM)
was speciﬁcally engineered for a lack of IgG FcR binding - a feature
that may have unexpectedly contributed to its failure in the clinic
[213,214]. Another feature of the antibody-based agents is that
they have two TNF binding sites, which stands in contrast to ONE (a
single recombinant pegylated extracellular TNFR) and CERT (a
pegylated single dimeric Fab’ Ig fragment). Thus, although these
agents all bind and neutralize TNF with high speciﬁcity and
afﬁnity, they differ signiﬁcantly in their relative bioavailability and
‘‘TNF:anti-TNF agent’’ stoichiometry. The importance of these
differences in biological properties between anti-TNF agents is
intriguing, and underscores the mechanisms of their action with
respect to their use in diverse pathologies in vivo. Indeed, even
within a single disease, it might be worth considering whether
these differences are actually revealing new disease sub-stratiﬁca-
tions. Taken together the biological effects of anti-TNF biologics
can be summarized into three main effector functions: ﬁrst, they
mop up excess soluble TNF (and/or LTa), reducing the endocrine
activity of these cytokines (Fig. 3, panels A). Secondly, they bind to
membrane-bound TNF (and/or LTa/b) complexes and either block
cell–cell contact and/or trigger reverse signaling (Fig. 3, panel B
and C). Third, they can act as agonists on FcR-expressing cells
(Fig. 3, panels C and D) – an effector function quite distinct from
their capacity to neutralize TNF. In addition, TNFR2 is highly
expressed on Treg cells [215], and a recent report demonstrates
that TNF antagonism restores normal function to dysregulated
Treg cells in patients with RA, in a dose-dependent fashion [216].
Moreover, phosphorylation of FOXP3 (a key transcription factor in
Treg function) is downregulated by TNF [216]. Further research soluble TNF (panel A) as well as membrane TNF (panel B). They also co-engage with
 (panel C). In addition, TNFR-based reagents can also bind and neutralize soluble or
Box 1. Indications for anti-TNF biologicals use in RA and/or
related conditions [270]
 American classification criteria for a diagnosis of RA, or
active ongoing RA defined as DAS score >5.1 with two
measurements (minimum 1 month apart), or other relevant
disease diagnosis.
 Failed standard therapy with at least two standard anti-
rheumatic drugs (hydroxychloroquine, sulphasalazine, pen-
icillamine, azathioprinem methotrezate, or leflumomide);
minimum 6 months or <2 months treatment if due to drug
intolerance or toxicity.
Exclusion criteria for anti-TNF biologicals in RA and related
conditions [269,349,350]
 Women who are pregnant or breast-feeding.
 Active bacterial or viral infection (includes live virus based
vaccinations).
 Septic arthritis of native joint.
 Septic arthritis of implant/prosthetic joint.
 New York Heart Association Grade 3 or 4 congestive cardiac
failure.
 History of demyelinating disease or present diagnosis of
Multiple Sclerosis.
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biologics and in the treatment of other inﬂammatory conditions.
Nevertheless, evidence is currently emerging that one of the main
effector mechanisms of anti-TNF biologics is to critically control
Treg cell function.
With respect to anti-TNF dietary compounds, curcumin appears
to inhibit TNF transcriptionally, acting at several levels, but
perhaps most importantly by inhibiting NF-kB [217,218]. It also
broadly inhibits molecules known to be important in TNF-induced
signaling, arachidonic acid metabolites such as phospholipase A2,
cyclooxygenases and 5-lipoxygenase [219,220]. Thalidomide is
similar in that, it too, inhibits TNF synthesis [193]. As discussed
above, TNF is produced by diverse myeloid cells including dendritic
cells, monocytes and macrophages including CNS microglia, and
curcumin dramatically alters gene expression in all these cells
[218,221–223]. Thus, curcumin and thalidamide are broad-acting
anti-inﬂammatory agents that inhibit the production of TNF,
amongst their other activities.
8. Anti-TNF therapeutics – adverse events and side effects: a
‘‘chicken versus egg’’ scenario?
With over a decade’s experience in the treatment of a spectrum
of rheumatic and inﬂammatory diseases several adverse events
have emerged. The most frequent of these are relatively minor
adverse events: injection site reactions and infusion reactions.
These are probably unavoidable, and in fact perhaps they are to be
expected, given the modes of administration are sub-cutaneous
injection or intravenous infusion, and the Ig-related properties
such as FcR binding (ADCC, ACC), etc. For the most part these agents
appear to be surprisingly well tolerated. The other obvious risk is
the development of anti-drug antibodies. This was initially thought
to be more likely for anti-TNF antibodies that contain murine Ig
components such as IFX [224], but neutralizing and immune
complex forming anti-drug antibodies can also arise during
treatment with fully humanized mAbs such as ADA [225]. Anti-
drug antibodies can result in the loss of clinical response [225,226]
as well as other adverse drug reactions, even acute hypersensitivity
(anaphlaxis) [227]. Interestingly, co-administration of immune
suppressants, such as methotrexate, generally reduces the inci-
dence of anti-drug antibodies [228]. It is also widely believed that
sub-therapeutic doses of anti-TNF biologics contribute to the
development of anti-drug antibodies, and hence that increasing
drug dose simultaneously raises in vivo levels of drugs through
‘‘trough’’ times (between doses), whilst simultaneously reducing
the risk of developing anti-drug antibodies; (for review see [229]).
Careful therapeutic monitoring of objective measures of disease
presentation, together with anti-drug antibody monitoring, are
therefore clearly required to ensure ongoing efﬁcacy and safety of
current anti-TNF biologics, as no therapeutic administration of
mAbs is considered to be completely without risk.
8.1. Anti-TNF induced imunosuppression and risks of infection
The immunoregulatory effects of TNF mean that anti-TNF
biologics create an immunosuppressed individual, which is
exacerbated by the concomitant use of additional disease
modifying anti-rheumatic drugs (DMARDs), e.g., methotrexate or
sulfasalazine, etc. (anti-TNF agents are FDA-approved and gener-
ally prescribed for patients whose disease had not responded to
ﬁrst-line DMARDs; see Box 1). Similary, in Crohn’s disease patients,
anti-TNF agents are often used together with azathioprine. As a
consequence, most patients receiving anti-TNF biologics are
profoundly immunosuppressed. The clinical use of systemic
anti-TNF biologics is therefore not infrequently associated
with worsening symptoms of infection, especially chronic andpersistent infection including tuberculosis, or latent viral infections,
such as varicella-zoster (chickenpox) or herpes zoster (shinges)
[230–233]. Cases of exacerbated legionella have also been added to
this list [234–237] and reports of severe acute respiratory virus
infections including new inﬂuenza and adenovirus infections are
often reported [238–240]. The US FDA recommends cessation of IFX,
ETA, etc., with onset of symptoms of virus infection, particularly
inﬂuenza and inﬂuenza-like illnesses.
With an increased risk of infection comes the issue of
vaccination, especially vaccines comprised of live microorganisms.
However, patients taking anti-TNF agents continue to mount
adaptive immunity, including B cell production of neutralizing
anti-inﬂuenza Ig, albeit with reduced numbers of circulating CD27+
memory B cells and lower neutralizing anti-inﬂuenza Ig titers, i.e.,
reduced vaccine immunity [241,242]. It also raises issues of
‘‘endogenous risk’’ within speciﬁc geographic locations and the
endemic levels of microorganisms in different countries, together
with varied healthcare capability and healthcare proximity/
availability. Thus, while differences in the incidence of reactivation
of tuberculosis have been reported, being higher with IFX and ADA
(both anti-TNF antibodies) treatment than with ETA (a TNFR-Fc)
[243,244] (due to differential inhibition of phagosome maturation
and function [142,245]), the relative risk warrants closer
consideration. For example, the relative endemicity of tuberculosis
in Asia, means that the risks of tuberculosis reactivation are greater
in Asia than they are in North America or Europe [246], and it is
here that the differences between anti-TNF biologic appear to
become clinically important. Nonetheless, as indicated above, it
should be remembered that most of these patients experiencing
exacerbated microbial infections are taking a powerful combina-
tion of immunosuppressive agents (for review see [247]), and thus
these anti-TNF agents may be undeserving of their reputation for
increased risk of infection entirely by themselves. Nonetheless,
patients taking anti-TNF biologics are advised to be aware of the
early symptoms of infection and to cease drug treatment when
infection is apparent.
8.2. Hematological malignancies
There are also several reports of patients on anti-TNF biologics
developing lymphomas and other hematological malignancies.
These include reports of lymphomas (Hodgkin’s lymphomas, B-cell
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unspeciﬁed lymphomas, and hepatosplenic T cell or gamma-delta
T cell lymphoma) and acute leukemias [248–250]. As a direct
consequence of the perceived increase in hematological malig-
nancy and widespread use of these and other immunosuppressive
agents, the WHO classiﬁcation of tumors now includes the
category ‘‘iatrogenic immunodeﬁciency-associated lymphoproli-
ferative disease’’ [251]. Nevertheless the actual reported incidence
of malignancy remains low in terms of relative risk expressed as
person/years, and a statistically signiﬁcant difference in lymphoma
incidence is difﬁcult to substantiate [250]. In fact a 2011 Cochrane
review, which takes into consideration some 163 randomized
controlled trials with over 50,000 participants, and 46 extension
studies with 11,954 patients, concluded that the rate of lymphoma,
and congestive heart failure, were not statistically signiﬁcant
[252]. However the risk of malignancy associated with anti-TNF’s
remains a concern because the statistical difﬁculty resides in the
low overall incidence of spontaneous transformation [250]. This is
consistent with murine studies where TNF gene knockout mice do
not spontaneously develop tumors by 12 months of age (Sedger L.,
personal communication) and although differences in spontaneous
tumor development are not always evident until moved onto a
tumor suppressor gene deﬁcient background [253], even p53- and
TNF- double-deﬁcient mice to not spontaneously develop tumors
more frequently than p53-null mice [254]. Thus the role for TNF in
tumor incidence appears to be in the development and regulation
of immunity, but not in tumorogenesis per se, nor even in the ﬁrst
phases of tumor immunosurveillance [255]. Finally, it may be
worth considering whether there is an increased risk of virally
transformed tumors. This is an area of ongoing interest in cancer
biology [256–258] and greater molecular interrogation of tumors
in patients taking anti-TNF biologics is required to rule out this
possibility.
8.3. Demyelinating events and neuropathies
As early as 2001 there were reports of demyelinating events
that appeared to be associated with the use of IFX and ETA for RA
[259]. Although the relationship to TNF blockade was unclear at
the time, these cases were considered adverse events to anti-TNF
treatment because they partially or completely resolved after
cessation of treatment [259]. As a result of these cases, multiple
sclerosis was quickly considered by a contraindication for the use
of anti-TNF agents. While similar cases continue to be reported
[260–262], it has been argued that the incidence of multiple
sclerosis in patients receiving anti-TNF agents is similar to that
which occurs in society in general [263,264]. Of particular note, the
ﬁrst comprehensive prospective study of demyelinating events
has recently been published. Here, 77 patients received a full
neurological examination including brain and spine magnetic
resonance imaging (MRI) and electrophysiological tests before
starting on anti-TNF biologics (IFX, ETA or ADA) for RA, psoriatic
arthritis or ankylosing spondylitis. Of these, 2 patients were found
to have lesions prior to anti-TNF treatment, and 4 developed
neurological symptoms (MRI-conﬁrmed demyelinating events),
but overall the rate of neurological adverse events was 4% and not
signiﬁcantly different from the non anti-TNF group [265]. Taken
together, one thing is clear: there is a need for careful monitoring of
patients on anti-TNF treatments. Although it is unclear whether
anti-TNF biologics constitute an a priori triggering event for
demyelination, it has been suggested that there are several ways in
which anti-TNF agents could be involved: (i) that they could
regulate auto-reactive (self CNS-speciﬁc) pathogenic T and B cells,
(ii) that they block TNF to alter downstream cytokine responses,
(iii) that they can neutralize TNF systemically but not within the
CNS, creating an artiﬁcially high local concentration of brain TNF(the so called ‘‘sponge effect’’), or (iv) that they permit release of a
latent or sub-acute CNS viral infection [266]. It is also possible that
anti-drug antibodies and immune complexes are contributory to
demyelination events, even if these Ig’s are not directed to self
CNS-speciﬁc antigens.
8.4. Potential impact on the cardiovascular system
Not long after the ﬁrst phase of anti-TNF-biologics became
widely used it was postulated that lowgrade chronic inﬂammation
was related to progression of congestive heart failure. However, a
clinical trial with IFX failed to demonstrate beneﬁt in congestive
heart failure, and in fact, quite unexpectedly, IFX at 10 mg/kg, was
found to be associated with worsening condition and mortality
[267]. Several additional case reports of worsening cardiac
condition also emerged [268], and consequently caution is advised
in using these drugs in patients with heart failure. In fact, the
2001 BSR guidelines state ‘‘patients should be carefully monitored
for congestive cardiac failure, ‘‘whilst’’ being treated with any anti-
TNF therapy. If symptoms and signs of congestive cardiac failure
are stable, treatment should still potentially be discontinued if the
beneﬁts of the anti-TNF therapy are only limited’’ [269,270]. How-
ever, there are also studies that indicate that this effect is minimal,
if indeed it is present, and it seems that the risk is associated with
concomitant RA and not with the anti-TNF biologics per se
[271]. One potential reason for this is that oxidative stress can be
triggered by downstream metabolites of TNF signaling, such as
arachidonic acid, and oxidative stress is strongly implicated in
cardiovascular endothelium health [272]. It has also been argued
that the reduction in inﬂammation and joint disease that anti-TNF
agents bring to RA patients, yield an overall net beneﬁt that
reduces the risks of cardiovascular disease [273]. Also that TNF can
inﬂuence plasma lipid proﬁles, but this too, remains controversial
[274]. More research is therefore needed to determine the effects
of anti-TNF biologics in cardiac disease, meanwhile, screening for
cardiac risk factors is important for RA patients receiving current
anti-TNF therapy.
9. What’s next for the current generation of anti-TNF biologics?
Can they be improved?
Anti-TNF biologics have arguably had stunning success globally,
to the extent that some might argue that a ‘‘next generation’’ of
reagents is not required. Indeed it is hard to think of another group
of biologic-based drugs that has demonstrated greater efﬁcacy
worldwide, and especially for a broad spectrum of autoimmune
and inﬂammatory diseases that once appeared for many patients
to be refractory to standard immunosuppressant therapies. That
these agents have changed the lives of so many people who were
otherwise crippled by rheumatic diseases underscores their
success, and their use in inﬂammatory bowel disease represents
another chapter of their success. Still, the plethora of case reports
and systematic analyses have documented varying degrees of
efﬁcacy, which remains an ongoing problem, and as many as one
third of patients achieve little or no beneﬁt. Moreover, the cost of
these agents and their potential for signiﬁcant side-effects
indicates that there is an urgent need for the early identiﬁcation
of treatment non-responders. Thus a new generation of anti-TNF
agents is still required.
The ﬁrst requirement for better identiﬁcation of treatment
responders and non-responders is the development of strong
objective guidelines for categorizing responsiveness. These must
be deﬁnitively measured for easily assessment and be clinically
meaningful. In the case of RA the presence of rheumatoid factor
(RF) antibodies (antibodies that bind to IgG) has long been
proposed to predict a more severe class of disease [275], and
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[276]. It has thus been suggested that RF and anti-citrullinated
protein antibodies might be useful predictors of disease severity
and indicators of anti-TNF responders [277]. However, this
remains unconﬁrmed, and in fact, at least two studies refute their
usefulness in identifying responders [278,279]. In contrast, a
recent study claims to have identiﬁed a 24 protein biomarker
signature of RA responders to ETA treatment [280], and there are
differences in peripheral blood leukocytes in RA patients over
controls, including mRNA-expressing CD16+ granulocytes, NK cells
and CD14dim monocytes [281]. Furthermore, analysis of circulating
miRNAs can also reveal candidate biomarkers of treatment
responders, and in fact, a 6 miRNA signature has recently been
reported to potentially identify TRAPS patients responding to
anakinra (IL-1R antagonist) [282]. Further validation of these
potential biomarkers in independent and larger cohorts will be
required to conﬁrm the validity of these molecules as biomarkers of
treatment responses.
In the case of Crohn’s disease, a clinical activity score known as
the ‘‘Crohn’s disease activity index’’ (CDAI), or equivalent, can be
used to objectively quantify symptoms. This includes a combina-
tion of CDAI, biomarkers such as serum C-reactive protein, serum
drug trough levels, and the presence and quantiﬁcation of anti-
drug antibodies [283]. Indeed, despite the regulatory approval and
success of anti-TNFs biologics in Crohn’s disease, approximately
50% of patients do not respond to ADA. Thus the deﬁnitive
identiﬁcation of responders from non-responders becomes para-
mount in patient management. Of these, sub-therapeutic ‘‘drug
trough’’ levels is thought to be critically linked to treatment
outcomes/non-responsiveness [284–286]. Of particular interest,
however, is a 2014 report demonstrating that expression of colonic
membrane TNF is a possible identiﬁer of anti-TNF therapeutic
responders [287]. In this remarkable study of 25 patients, in vivo
ﬂuorescent colonoscopy imaging with GMP-prepared FITC-conju-
gated ADA, demonstrated that patients with high numbers of
membrane TNF-positive mucosal immune cells strongly correlate
with mucosal healing and ADA treatment efﬁcacy [287]. The
membrane TNF-expressing cells were mostly lamina propria CD14
macrophages and CD4 T lymphocytes [287]. This important report
therefore provides a basis for rational identiﬁcation of anti-TNF
drug-responders, while simultaneously identifying dominant
etiopathological elements of Crohn’s disease. It also potentially
reveals a mode of efﬁcacy of anti-TNFs, i.e., the ability of these bio-
reagents to detect, neutralize and/or eliminate membrane TNF
expressing cells. The obvious limitation for broad-scale use of this
new knowledge, however, is the availability of confocal laser
endomicroscopy, not to mention the difﬁculty in accessing skilled
and time-consuming analysis of the image data it provides. Thus,
there remains an ongoing critical need to develop novel serum
biomarkers of drug responsiveness, not just in Crohn’s disease, but
for all rheumatic diseases for which anti-TNF biologics are utilized.
Additional serum proteomic and circulating microRNA studies
reﬂecting contemporary technologies and capabilities are there-
fore still needed.
Another approach to identifying anti-TNF drug-responders
from non-responders is through pharmacogenetic analyses.
Various studies of TNF biology revealed genetic polymorphisms
in the TNF gene promoter sequence, including 1031T/C, 863C/A,
857C/T, 376G/A, 308G/A, 244G/A, 238G/A, +70C and
+489G/A [27], where some are suggested to be linked to increased
TNF production [288]. It stands to reason that increased TNF
production may be linked to anti-TNF therapeutic success, i.e., to
sub-therapeutic anti-TNF doses, and thus these alleles represent a
potential genetic basis for deﬁning drug-responders. However,
even with a clinical sub-types stratiﬁcation analysis within speciﬁc
inﬂammatory diseases, these studies have yielded mixed results[289–294]. It is probably fair to conclude that no single or simple
combination of single nucleotide polymorphisms (SNPs) has been
found that deﬁnes the failure of anti-TNF agents in non-responding
patients. On the other hand, TNF promoter SNPs may deﬁne disease
sub-type risks [295], and interestingly, additional non-TNF
candidate alleles are emerging [289–294], including in genes such
as NLRP3 and IFN [292,296] – i.e., in molecules involved in sterile
inﬂammation [297,298] now additionally implicated in the auto-
immune inﬂammation of Crohn’s disease [299] and RA [292,296].
Similarly, polymorphisms in MAPK have also recently been
implicated in anti-TNF treatment responsiveness in RA [300]. Time
will tell if a particular spectrum of symptoms, a series of SNPs,
and/or a panel of serum biomarkers can deﬁne anti-TNF treatment
responders versus non-responders.
There are now seven FDA registered anti-TNFs biologics
(including recently registered biosimilars), an IL-1 receptor antago-
nist (ankinra; Kineret1), and anti-IL-1b (Canakinumab1) and anti-
IL-6-Receptor mAbs (tocilizumab; tradenames Actemra1 and
RoActemra1), all with considerable overlap in the clinical indica-
tions for FDA approved use in RA and other autoinﬂammatory
diseases [301]. Deﬁning which reagent is best suited to a speciﬁc and
clinically deﬁned disease type goes hand-in-hand with the ability to
pre-identify drug non-responders. Arguably the most convincing
current lead in identifying anti-TNF responders is the recent
demonstration of locally high membrane TNF-expressing cells
which correlates with anti-TNF efﬁcacy in Crohn’s patients, as
mentioned earlier [287]. Indeed, it is tempting to consider what
beneﬁt might be afforded to Crohn’s patients with low colonic TNF if
they were treated with anti-IL-l neutralizing antibodies instead.
Alternatively, other cytokine neutralizing mAbs might be beneﬁcial,
as it has also been demonstrated that anti-TNF non-responding
psoriatic arthritis patients experience beneﬁt from ustekinumab
(Stelara1), a new IL-12/23 p40 neutralizing mAb [302,303]. Taken
together these examples highlight the need for a more personalized
approach to the treatment of inﬂammatory diseases, albeit without a
current and proven directory for pre-deﬁning successful treatments.
10. Next-generation anti-TNF agents: What are they? How will
they be possible?
What are these next generation anti-TNF-agents? What will
they look like? How can they achieve what the existing group of
anti-TNF biologics fail to do in some patients, i.e., achieve disease
remission? The ﬁrst thing a next-generation anti-TNF agent might
do is accommodate an easier mode of delivery whilst maintaining
pharmacokinetic goals, since all of the current agents are delivered
by sub-cutaneous injection or intra-venous infusion, apart from
the non-TNF speciﬁc curcumin and thalidomide (see Table 1). Oral
delivery, although highly desirable, is extremely difﬁcult – if not
impossible – if the object is systemic suppression of TNF by large
bio-molecules. Smaller, non-Ig-based molecules, are therefore
likely to be required, albeit that this may also bring about the loss
of the Fc-related effector functions, as discussed above.
10.1. Peptidomimics and PLAD only domain proteins
The ﬁrst attempts at non antibody-based reagents comprised
smaller molecules known as ‘‘peptidomimetics’’. These were
simply peptides that represent the TNF contact region of TNFR1,
designed from computer-simulations, and which function to block
TNF from interacting with its receptor [304]. Next, with knowledge
of TNFR dynamics came a ‘‘domain-only’’ protein called the ‘‘pre-
ligand binding assembly domain’’ (PLAD). The PLAD resides within
the N-terminus of TNFRs where it functions to permit TNFR
homotypic interactions that facilitate ligand binding-induced
TNFR signaling [50]. The domain is also required for virally
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TNF-induced cell death [305] – just one of many examples of how
viral evolution generates functional mechanisms of potent
inhibition and neutralization of TNF [97]. The PLAD itself is only
approximately 44 amino acids in length and at least two groups
have produced soluble recombinant human TNFR1 ‘‘PLAD-only’’
proteins [306,307]. At present there is ongoing disagreement about
how PLAD-only proteins work. For example, the viral PLAD-
containing TNFRs clearly subvert TNFRs by acting from an
intracellular location since extracellular puriﬁed vTNFRs show
no ability to interfere with cellular TNFRs [305,308]. In contrast,
the extracellular recombinant TNFR1 PLAD-only proteins report-
edly prevent TNF-induced L929 cell death [306] and its in vivo
administration ameliorates arthritis in mice [307]. A TNFR1 PLAD-
Ig-Fc fusion protein has also now been produced. It also reportedly
reduces TNF-induced autoimmune inﬂammation and the expan-
sion of Th17 cells in autoimmune disease in mice [309]. It currently
remains unclear whether PLAD-only proteins require uptake from
myeloid cells, such as inﬂammatory monocytes, and/or whether
the discrepancies between viral and cellular PLAD proteins result
from the viral proteins being homologous to TNFR2, compared to
the recombinant human PLAD-only proteins being TNFR1.
Nevertheless, although they show promise in animal models
of disease, their delivery requires repeated injections. While
they may be smaller than anti-TNF mAbs, the pharmacokinetics of
PLAD-only proteins in humans is unknown and there is no
advantage in the mode of delivery over the currently approved
anti-TNF biologics.
10.2. Small molecule inhibitors – is this still an achievable goal?
The question still remains open as to why small molecule
inhibitors of TNF or TNFR have been slow to emerge, especially with
the availability of powerful contemporary computer modeling
software. This area is still potentially the most proﬁtable, since
small-molecules inhibitors are likely to be far cheaper to produce
than mAb or Ig-Fc-based fusion proteins. Early reports of small
molecule inhibitors of TNF/TNFR were intriguing; 4 compounds that
bound reversibly to TNFR1 in the dark, but irreversibly in light, have
been reported [310]. Structural studies indicated that these
molecules interact with sites on TNFR that prevented TNF
association with TNFR1 [310]. That the interactions are relatively
weak and reversible in the dark meant they were not particularly
attractive for further clinical development – although they
conﬁrmed that a potential target site is the regions on TNFRs that
interact with TNF. Another early report of a small molecule inhibitor
preventing TNF binding to TNFR, actually interacts with TNF at
amino acid Tyr-119 (which residues deep within TNF trimer) and not
with TNFR itself [311]. This intriguing molecule disrupts the
formation of TNF trimers [311] which implies that TNF exists in
an equilibrium between monomeric and trimeric TNF, at least at
some stage in its production and maturation. Unfortunately there
have been no further reports of any of these compounds, suggesting
that they have insufﬁcient physiological potency, or that there are
issues with solubility or toxicities in physiological conditions.
A novel chemically synthetized anti-TNF compound has
recently been reported, C87, that binds directly to TNF and
prevents TNFR signaling [312]. It was found from an initial screen
of approximately 90,000 compounds that interact with a 7-amino
acid region comprising the TNF-interacting site on TNFR1. C87 is a
potent inhibitor of TNFR-1 mediated activation of caspase-8,
phosphorylated JNK and NF-kB [312]. It prevents L929 cell
production of TNF-induced cytokines and chemokines and has
been trialed in animal models, where it reportedly inhibits LPS-
induced hepatic inﬂammation in mice [312]. This is one of only a
few reports of a small-molecule inhibitor of TNF with in vivo efﬁcacy.The remaining challenge is to determine if it is pharmacologically
stable and non-toxic with longer-term use. In an alternative
approach, at least three groups have developed small molecule
inhibitors of the membrane TNF releasing enzyme TACE. All are
soluble at physiological pH and effective at reducing LPS-induced
TNF, and rodent arthritis (when administered orally) [313–315].
However, with limited recent publications, the state of clinical
development of these molecules is unknown. While the hunt
continues for new small molecules inhibitors, one cannot forget
thalidomide, which is effectively a soluble, orally administered,
small molecule that inhibits TNF synthesis. As stated above,
thalidomide inhibits the production of TNF, but also IL-6 and IL-1,
acting by inhibiting certain pathways of NF-kB and MyD88 signaling
[194]. Taken together these examples prove that it is possible to
speciﬁcally design and synthesize small-molecule inhibitors of TNF,
TNFR, or TACE, yet none are presently available or approved for
therapeutic use. Thus the goal remains to ﬁnd small molecule
inhibitors of TNF that are biologically active after oral administra-
tion, present in vivo at pharmacologically meaningful concentra-
tions, and that are physiologically well tolerated; a combination of
challenges that may yet turn out to be too difﬁcult to meet.
10.3. The potential for cell speciﬁc drug targeting
TNF-expressing cells are implicated in most inﬂammatory
diseases and conditions. For example CD14-dim monocytes and
tissue macrophages, as well as granulocytes and natural killer cells
can be detected by biotinylated-IFX in RA patients [316]. Further-
more, their numbers are diminished after IFX treatment [316]. This
begs the question as to how the current anti-TNF biologics,
especially the antibody-based reagents, might be speciﬁcally
targeted to inﬂammatory cells, leaving normal TNF-mediated
physiological functions unaffected in non-immune cells. There is
also the issue of self-perpetuating immunopathology driving
further TNF production, for example, through the production of
anti-drug antibodies and their potential ability to opsonize and/or
aggregate and thereby activate monocytes and other FcgR
expressing cells [317]. Of interest is the recent report of the use
of immune modifying microparticles for the speciﬁc elimination of
inﬂammatory monocytes [318]. On this basis one can envisage the
potential for future liposome- or microparticle- mediated targeting
of inﬂammatory monocytes/macrophages, i.e., for the speciﬁc
delivery of anti-TNF biologics to block the production of TNF by
phagocytic monocytes.
Also attracting increasing attention, is the exciting use of dual-
speciﬁc engineered mAbs, with at least two such reagents already
FDA approved for human clinical use: catumaxomab (Removab1;
EpCAM/anti-CD3) – approved for malignant ascites, and blinatu-
mab (BiTE1; anti-CD19/anti-CD3) approved for acute lympho-
blastic leukemia and lymphoma [319]. Precisely how they would
work in vivo, and whether they prove to be safe, and tolerated long-
term (due to immunogenicity concerns), is yet to be fully
determined, as there are already reports of anti-drug antibodies
to these unnatural Igs, and other complications, but this will
become evident with more time and clinical experience [320,321].
Sufﬁce to say they both bring T cells to tumors cells, and mediate
ADCC through FcR binding [319]. Newly re-engineered, dual-
speciﬁc, anti-TNF antibodies could similarly offer the possibility of
TNF neutralization in speciﬁc cell types. Finally, antibody
engineering also offers the potential for altered in vivo half-life
or effector function via differing afﬁnities for FcR [322].
10.4. TNF-blockade in neurological systems – the next frontier
The blood–brain barrier of endothelial cells constitutes a
physiological boundary preventing efﬁcient entry of therapeutic
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this area is the potential use of Fc Ig targeting to neonatal Fc
Receptors (FcRn) which permits Ig/mAb transcytosis across the
blood–brain barrier [323,324] and thus providing opportunities for
therapeutic antibody-mediated TNF neutralization within the CNS.
Of note, a TNFR2 fusion protein has been engineered for expression
as a transferrin-receptor-speciﬁc Ig constant-domain tag, i.e.,
speciﬁcally for delivery across the blood–brain barrier, into the
CNS [325,326]. It has already been used in mice to neutralize
pathology associated with ischemic stroke [326]. These ﬁndings
are consistent with the fact that (i) TNF is high in CSF and serum of
humans after stroke [327], (ii) that TNF transgenic rats are more
susceptible to ischemic stroke [328,329], and (iii) that the
engineered transferrin-receptor speciﬁc-mAb-TNFR2 fusion pro-
tein can be detected within the CNS after intravenous or sub-
cutaneous injection [330]. Another approach for entry into the CNS
might be to harness cell-penetrating peptides [331], but this has
not yet been explored in the context of anti-TNF biologics, possibly
because of the relatively large size of Ig-based biomolecules.
Nevertheless this approach might be signiﬁcant with smaller, more
selective, anti-TNF peptidomimetics.
On the other hand tag-speciﬁc CNS-targeting may not always
be necessary, since perispinal injection of radiolabelled-ETA can
be detected within the cerebrospinal venous system within
minutes [332]. Indeed, it has been reported that perispinal ETA
produces multiple effects in Alzheimer’s patients, including
improved cognitive function, mood, memory and motor function
[332]. However, independent conﬁrmation of these intriguing
responses will require a double-blind trail. Peripsinal ETA has
also been reported to relieve neuropathic pain such as sciatica
[333–335], although this also requires replication in controlled
trials. Nevertheless, TNF blockade with IFX inhibits nociceptive
pain responsiveness in mice [333], and it had long been a
conundrum that RA patients report feeling considerably better
long before their joint damage has had time to heal – a key factor in
patient’s perceptions of therapy success [336]. These ﬁndings are
not surprising considering that TNF synthesis inhibitors curcumin
and thalidomide can both offer relief for neuropathic pain
[337–340]. The application of anti-TNF biologics for CNS-related
pathologies such as Azlheimer’s disease is the current frontier.
TNF is now also strongly implicated in playing a role in the biology
of depressive and bipolar disorders [341–344]. If successful, then
the search for non-injectable anti-TNF inhibitors will become
increasingly important given the need for an aging dementia-
affected patient population being able to self-administer medica-
tions. Careful dosing and monitoring will also be required – the
role of TNF in normal neurobiology is paramount to health; over-
inhibition may be detrimental given that genetic TNFR-deﬁciency
exacerbates Alzheimer’s-like symptoms in mice [345]. Indeed,
one envisages that it is of paramount importance in brain more
than any other tissue, that anti-TNF agents achieve the ﬁne
balance of inhibiting inﬂammation while permitting essential
functions for normal tissue homeostasis and health.
11. Summary: an exciting future
It is now some 15 years since ETA was ﬁrst FDA approved to
ameliorate inﬂammation in the treatment of methotrexate-
refractive RA. Currently ﬁve TNF-speciﬁc monoclonal antibodies
are also approved to treat inﬂammatory disorders. Despite the
well-documented risks associated with their use, and the fact that
they still cost between $US17,000 and $25,000 per patient/year
[346], they have been proven to provide a signiﬁcant health beneﬁt
to many. Not only are they broadly successful in ameliorating
inﬂammation in several disease settings, but also their off-label use
is still expanding [332]. Looking back, one of the most remarkableand perhaps unexpected revelations that has come from the large-
scale use of anti-TNF biologics, is that they have taught mankind as
much about normal biology as they have about immunopathology.
The current challenges are (i) to better pre-identify or predict the
non-responders, i.e., prior to treatment, (ii) to better tailor drug
delivery to permit normal physiological effects of TNF in non-
diseased tissues, and (iii) to develop more selective anti-TNF
agents that block only select aspects of TNFR signaling. Finally,
with respect to RA, there is also now considerable evidence that
mechanisms of etiopathology change over time [316] and this is
also likely to be true for other inﬂammatory diseases. Thus more
careful patient monitoring over time may implicate the need for
dose adjustments and/or for changes in the anti-cytokine therapies
being delivered – several neutralizing mAbs are now available. This
highlights, once again, the need for more personalized medicine, as
well as ongoing medical education for clinicians who prescribe
these reagents. It also indicates that anti-TNF biologics, although
effective, are expensive and infrequently bring complete and
durable disease-free remission. Arguably, the biggest, morally
compelling challenge, is to use the current knowledge to develop
more affordable anti-TNF agents; ones that will be both effective
and available to all independent of ﬁnancial status [347]. With
signiﬁcant successes already realized in RA and related autoin-
ﬂammatory disorders [206,348], anti-TNF agents move bravely
into a new era of personalized medicine and the search for better
treatments for chronic neurological diseases.
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